

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/013965 A1

(51) International Patent Classification⁷: A61K 31/201,
A61P 11/00, 11/06, 19/02

(21) International Application Number:
PCT/EP2003/014592

(22) International Filing Date:
19 December 2003 (19.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
103 32 712.6 18 July 2003 (18.07.2003) DE

(71) Applicant (for all designated States except US): COGNIS
DEUTSCHLAND GMBH & CO. KG [DE/DE]; Henkel-
strasse 67, 40589 Düsseldorf (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BELL, Doris


[DE/DE]; Am Ellerforst 43, 40627 Düsseldorf
(DE). WEISS, Albrecht [DE/DE]; Forellenweg 37,
40764 Langenfeld (DE). STRUBE, Albert [DE/DE];
Max-Ernst-Strasse 107, 41470 Neuss (DE). FABRY,
Bernd [DE/DE]; Danziger Strasse 31, 41352 Korsch-
broich (DE). JAHREIS, Gerhard [DE/DE]; Hinter dem
Dorfe 32, 07751 Jena (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: USE OF CIS-9, TRANS-11 ISOMER OF CONJUGATED LINOLEIC ACID (CLA) FOR TREATING INFLAMMATORY DISEASES



A: Modulation of LPS/serum-stimulated BEAS-2B by *cis*-9,*trans*-11 CLA and LA. The cells were incubated with the fatty acids at increasing concentrations for 24 h. (A) shows relative cell numbers compared with the unstimulated control (= 1) (B) depicts relative stimulation or inhibition observed. Data are means \pm SEM of 6 independent experiments performed at different days ($n = 6$). Connection of bars represents data with statistically significant differences ($p < 0.05$)



B: Modulation of LPS/serum-stimulated NHBE by *cis*-9,*trans*-11 CLA and LA. The cells were incubated with the fatty acids at increasing concentrations for 24 h. (A) shows relative cell numbers compared with the unstimulated control (= 1) (B) depicts relative stimulation or inhibition observed. Data are means \pm SEM of 6 independent experiments performed at different days ($n = 6$). Connection of bars represents data with statistically significant differences ($p < 0.05$)

(57) Abstract: The use of the *cis*-9, *trans*-11 isomer of conjugated linoleic acid (CLA) is suggested for fights ing inflammatory diseases.

WO 2005/013965 A1



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Use of *cis*-9,*trans*-11 isomer of conjugated linoleic acid (CLA)

Object of the invention

The present application belongs to the area of pharmacy and refers to a new medicament for fighting inflammatory diseases, preferably respiratory diseases like, e.g., asthma.

State of the art

Asthma bronchiale is an inflammatory respiratory disease which is accompanied by an increased sensibility of the respiratory channels for various stimuli and a reversible bronchial constriction. The airway epithelium is the first tissue layer to encounter environmental stimuli such as inhaled allergens or microbes and plays a pivotal role in the inflammatory network seen in airways during asthma attacks. The evolution of asthma is primarily based on the inflammation of the bronchial mucous membrane, where mast cells, T-lymphocytes, granulocytes, and inflammation mediators like, e.g., histamine are considered to be seriously involved. Upon exposure to a stimulant, the epithelial cells by themselves will express and release a variety of inflammatory mediators which act in a paracrine, autocrine or endocrine fashion to propagate the disease development. Increased IL-6 and IL-8 production has been reported in airway epithelial cells from patients with bronchial asthma. Recently it has been demonstrated that activation of the nuclear peroxisome proliferator-activated receptor- γ (PPAR γ), which is constitutively expressed in bronchial epithelial cells, dramatically inhibits production of inflammatory mediators, suggesting that PPAR γ may act as a negative immunomodulator in the airways by protecting non-lymphoid tissue from cytokine-mediated events associated with immune stimulation. Similar to other steroid hormone receptors, PPAR γ requires activation by a ligand in order to modulate gene expression by interacting with specific DNA response elements located upstream of responsive genes encoding for inflammatory mediators.

People suffering from asthma show a bronchial hypersensitivity in the early phase of disease which means that the bronchial system reacts with contraction and an overproduction of slime even in case of rather weak and usually neutral stimuli. The dominant role in the pathogenesis of the *asthma bronchiale* is a spontaneous reaction of type I which is mediated by antibodies of the IgE type. Said antibodies recognise specific allergenic compounds as invaders, form complexes with said allergens in order to stimulate mast cells to degranulate and to emit messenger compounds like, e.g., histamine. These so-called mediators start a chain of reaction and effect an endobronchial obstruction by

- bronchial spasm (spasmodic contraction of the medial and small respiratory channels),
- swelling of the mucous membrane and inflammatory infiltration of the mucous membrane, and
- overproduction of viscous slime in the respiratory system.

As a result the respiratory system becomes blocked and the patient suffers from not getting enough breath. Besides the IgE-mediated spontaneous Type I reaction which usually occurs after a couple of minutes after the stimulation, further allergic reactions are possible even after some hours. It is known that some patients show both types of reaction. Although usually one allergen is responsible for an attack in the beginning of an allergic asthma, however, in the course of the disease other allergenic factors may become important, too, so that a prophylaxis by eliminating potential allergenic factors becomes rather difficult.

Besides bronchial dilatarding agents, asthma therapy uses anti-inflammatory medicaments:

- *Glucocorticosteroids* show anti-inflammatory, anti-allergic, and immune suppressive effects, increase the mucociliar clearance and inhibit the production of inflammation mediators. Further, they readjust the sensibility of the beta-receptors of the respiratory systems for beta-sympathomimetica. Unfortunately, the compounds need hours to become effective, even if applied intravenously, so that they are fully useless in case of an acute attack. In addition, glucocorticosteroids are know for negative side effect, for example an increased glucose concentration in the serum, unwanted fat deposition in the tissue, osteoporosis and skin atrophie.
- By means of *antihistaminica* the messenger histamine which is responsible for allergic reactions is neutralised and emitted in the course of an asthma attack. Antihistaminica inhibit the expression of histamines by the mast cells of the mammal by stabilising them. As a result, the swelling of the mucous membranes goes down, accompanied by

an anti-inflammatory effect. Unfortunately, these medicaments are only useful for prophylaxis but unsuitable for fighting a spontaneous asthma attack.

Therefore, it has been an object of the present invention, particularly with respect to the increasing number of resistances and the need for increasing the number of technical means, to identify new compounds which simultaneously inhibit cell proliferation and expression of cytokines, and which show an anti-inflammatory effect in order to fight diseases of the respiratory system and to develop a new medicament which is useful to prevent and to fight spontaneous asthma attacks or at least spend relief, mainly during the sleeping phase.

Detailed description of the invention

Object of the invention is the use of *cis-9,trans-11* isomer of conjugated linoleic acid for the production of a medicament for fighting inflammatory diseases and for a nutrition, functional food or dietary supplement agent.

Surprisingly it has been found in vitro that the *cis-9,trans-11* isomer of conjugated linoleic acid - compared to other CLA isomers in general and, more specifically, compared to non-conjugated linoleic acid -

- (i) inhibits cell proliferation predominantly of epithelial cells and mainly of bronchial epithelial cells for up to 30 %,
- (ii) support of apoptosis of eosinophilic granulocytes, and
- (iii) reduced the expression of pro-inflammatory cytokines like IL-6 for about 70 and of IL-8 for about 50 % (compared to a placebo).

The inhibition of cell proliferation, particularly the proliferation of cells of the immune systems involved in immune response and specific cytokine expression, preferably within cells of the bronchial system or the cartilage tissue of the joints, are accompanied by an anti-inflammatory effect which one can use for fighting

- hypersensitivity of the bronchia,
- respiratory diseases, particularly asthma, and
- rheumatic diseases, particularly rheumatic arthritis,

but also for reducing the symptoms of inflammation induced diseases in general, like e.g. rheumatic pains, Alzheimer's disease, arteriosclerosis, *morbus crohn*, *colitis ulcerosa* and the like.

5

Conjugated linoleic acid

Conjugated linoleic acid (CLA) represents a commercially available process which usually is obtained by base-catalysed isomerisation of sunflower oil or their respective alkyl esters and subsequent isomerisation in the presence of enzymes. CLA is an acronym used for positional and geometric isomers deriving from the essential fatty acid linoleic acid (LA, *cis*-9,*cis*-12-octadecadienoic acid, 18:2n-6). Soon after its initial isolation from grilled ground beef in 1987, CLA was found to exercise pleiotropic beneficial effects spanning from chemoprotection of carcinogenesis, atherosclerosis, and diabetes to inflammation. CLA has several structural and functional properties that are different from those of all-*cis*-nonconjugated polyunsaturated fatty acids. Namely, the non-methylene interrupted double bond system seems to be decisive for modulating cellular processes that might lead to the observed effects. Emerging evidence has indicated that individual CLA isomers act differently in the biological systems and contribute differently in their beneficial or potential side effects. The *cis*-9,*trans*-11 CLA-isomer was most efficacious in inhibiting the growth of cancer cell lines *in vitro* and *in vivo*. In contrast, *trans*-10,*cis*-12 CLA was observed to have a greater impact on lipid metabolism and adipogenesis. Recently, several studies have demonstrated the ability of CLA to reduce levels of pro-inflammatory eicosanoids such as prostaglandins of the 2-series. Until now, however, there is no specific way to predict the properties of certain isomers, therefore, the identification of new applications and uses is still a question of trial and error. From a physiological point of view the use of the *cis*-9,*trans*-11 isomer according to the present invention is of special importance having at least 30, preferably at least 50 and most preferably at least 80 % b.w. of said *cis*-9,*trans*-11 isomer – calculated on the total CLA content of the crude mixture. In addition, it has been found advantageous if the content of the *trans*-10,*cis*-12 isomer is at most 45, preferably at most 10 % b.w. and most preferably is less than 1 % b.w., and the sum of 8,10-, 11,13- and *trans,trans*-isomers in total is less than 1 % b.w. – again calculated on the total CLA content. Such products can be found in the market for example under the trademark Tonalin CLA-80 (Cognis). Usually, the daily dosage of CLA is 0.05 to 5, preferably 2.0 to 4 g/day.

35

Form of application

cis-9,trans-11 CLA or a respective medicament comprising said CLA isomer are usually applied either sub-cutaneously, intramuscularly, per inhalation, *per infusionem* or orally – the latter for example in form of a dietary supplement, e.g. in form of a liquid composition or a capsule – or inhaled as a spray. Beside this, a topical application – especially for fighting rheumatic pains – is also possible.

Examples

Materials and Methods

- 5
- *Cell cultures.* The transformed human bronchial epithelial cell line BEAS-2B (Clonetics Cell Systems, St. Katharinen, Germany) and the normal human bronchial epithelial cell line in primary culture (American Type Culture Collection, Manassas, VA, USA) were cultured in T-25-tissue flasks in bronchial/tracheal epithelial cell basal medium (BEBM) supplemented with a variety of growth factors including bovine pituitary extract (0,052 mg/mL), human recombinant epidermal growth factor (0,5 ng/mL), hydrocortisone (0.5 µg/mL), epinephrine (0.5 µg/mL), transferrin (0.01 mg/mL), insulin (5 µg/mL), retinoic acid (0,1 ng/mL), triiodothyronine (6.5 ng/mL), gentamicin (0.05 mg/mL) and amphotericin (0.05 µg/mL), all purchased from Clonetics Cell Systems (St. Katharinen, Germany). Cultures were held at 37 °C in a humidified atmosphere of 5 % CO₂ in air and the medium was changed every other day.
 - *Stimulation of cells and fatty acid supplementation.* *Cis-9,trans-11-CLA* and linoleic acid (LA) were obtained from Matreya Inc. (Pleasant Gap, Pennsylvania, USA). Purified fatty acids in oil form were dissolved in 96 % ethanol to give a 20-mM stock solution, which was further diluted in growth medium to produce the range of test concentrations (20 µg/mL, 10 µg/mL and 5 µg/mL CLA and LA, respectively). At confluence the cells were detached by exposure to trypsin/EDTA solution (0.05/0.02 % in Ca²⁺- and Mg²⁺-free phosphate buffered saline; Biochrom AG, Krefeld, Germany) and reseeded in 12-well plates at a concentration of 1×10⁵ cells/well and cultured for 24 h to allow the cells to attach to the substratum. The medium was then replaced and a final volume of 1 ml of each CLA- and LA-test concentrations, supplemented with 5 µg LPS/mL (lipopolysaccharide, E-coli serotype 026:B6, Sigma, Taufkirchen, Germany) and 10 % serum from allergic donors, was added to the wells. A similar volume of fatty acid-free medium containing the indicated stimuli and 0.4 % ethanol, corresponding to the max. volume in experimental wells, was used in stimulated control. 1 ml of fresh growth medium containing 0.4 % ethanol without any fatty acid and stimuli underwent the same measures of preparation and represented the unstimulated control. After incubation for 24 h at 37 °C, supernatants were harvested, separated from non-adherent cells and cell debris by centrifugation (1300 rpm, 10 min), and kept at -20 °C until cytokine analysis. Cells were trypsinised to determine cell numbers and allow quantification of differences in cell proliferation in response to different treatments.

- *Measurement of IL-6 and IL-8 in cell culture supernatants.* IL-6 and IL-8 production of epithelial cells were estimated in duplicate by enzyme-linked immunosorbent assay using commercially available ELISA kits (Pharmingen, Heidelberg, Germany) according to the manufacturer's guidelines. Standard curves and blank buffer were included in duplicate in each assay. When necessary, samples were diluted to fit into the assay range. Specific interleukin concentrations were expressed as picograms of interleukin per millilitre.
- *Estimation of cytokine gene expression with RT-PCR.* Cultures of BEAS-2B and NHBE at an initial density of 1×10^5 cells/well were stimulated as described above and treated with *cis*-9,*trans*-11-CLA or LA in the highest concentration (20 $\mu\text{g/mL}$) for 4 h or 12 h before total cellular RNA was isolated for cytokine gene expression analysis by reverse transcriptase-polymerase chain reaction. Total RNA preparations were performed by DNase treatment according to the standard protocol of the High-PureTM RNA isolation kit from Roche (Mannheim, Germany). For RT-PCR analysis, first strand cDNA was synthesized from extracted RNA using random primers, reagents and conditions supplied in the ProSTARTM First-Strand RT-PCR kit from Stratagene (Amsterdam, Netherlands). One-tenth of the synthesized cDNA was subjected to PCR-amplification in a total volume of 25 μl . The primers for IL-6 and IL-8 DNA amplification were designed from published sequences as follows:

IL-6 primer forward: 5'-CCCAGTACCCCCAGGAGAAGAT-3'

and reverse: 5'-CTGCGCAGAATGAGATGA-GTTGTC-3',

IL-8 primer forward: 5'-CTTGGCAGCCTTCCTGATTT-3'

and reverse: 5'-CTCAGCCCTCTTCAAAAAC-3',

and gave PCR products of expected sizes of 507 bp and 200 bp, respectively. Primer sequences for the housekeeping gene cyclophilin as internal control were: forward 5'-CATCTGCACTGCCAAGACTG-3' and reverse 5'-CTGCAATCCAGCTAGGCATG-3', defining a 326 bp DNA fragment. The PCR conditions were as follows: initial denaturation at 95 °C for 5 min to activate the AmpliTaq DNA polymerase (Roche, Mannheim, Germany), followed by 30 cycles of 95 °C for 1 min, annealing for 1 min, extension at 72 °C for 1 min, and a final 10 min elongation step at 72 °C. Annealing for the IL-6 primer pair was performed at 57 °C, for the IL-8 primer pair at 58 °C and for that of cyclophilin at 60 °C. PCR reaction products were separated by flat bed electrophoresis in 1,5 % agarose gels (Roche, Mannheim, Germany), stained with ethidium bromide, recorded using a gel-

documentation-system and analysed densitometrically with Phoretix 1D Advanced Software (Biostep, Jahnsdorf, Germany).

- *Statistical analysis.* To determine significant differences among the treatment groups, the data were evaluated with the Wilcoxon matched-pairs signed-ranks test using SPSS software (version 10.07) and are reported as the means \pm SEM of at least three independent experiments, each done in duplicate. Significance of difference was set at $p < 0.05$.

Example 1a

cis-9,trans-11-CLA prevented stimulus-induced increase of proliferation

To establish the effects of *cis-9,trans-11-CLA* in comparison to LA on proliferation of stimulated normal (NHBE) and transformed human bronchial epithelial cells (BEAS-2B), cells grown in medium containing 5 μg LPS/mL and 10 % serum from allergic donors and supplemented with either *cis-9,trans-11-CLA* or LA at different concentrations were harvested after 24 h and cell numbers determined. Exposure of cells to the indicated stimuli without any fatty acid (control+) caused a markedly enhanced proliferation compared with the unstimulated control in both BEAS-2B (by 12.9 ± 3.5 %) and NHBE (by 12.6 ± 3.2 %). Incubation with 20 $\mu\text{g/mL}$, 10 $\mu\text{g/mL}$ and 5 $\mu\text{g/mL}$ *cis-9,trans-11-CLA* significantly prevented the stimulus-induced increase dose-dependent significantly ($p < 0.05$) in BEAS-2B for all tested concentrations (by 32.7 ± 5.0 %, 19.3 ± 5.0 % and 7.9 ± 5.1 %, respectively) and in NHBE for 20 μg and 10 μg *cis-9,trans-11-CLA/mL* (by 17.4 ± 2.8 % and 15.4 ± 3.6 %). Treatment with LA under identical conditions led to a small and not significant inhibition of proliferation after 24 h using the maximal concentration (by 4.7 ± 6.9 % in BEAS-2B and 8.4 ± 2.1 % in NHBE). At lower concentrations, LA caused cell growth. Modulation of proliferation by the isomer was significantly different from that seen in LA-treated BEAS-2B, for all concentrations. The results are shown in Figures 1A and 2B.

Example 1b

Modulation of cytokine expression by fatty acid treatment

IL-6 and IL-8 secretion was examined by ELISA in culture supernatants of BEAS-2B and NHBE after 24 h of incubation with different concentrations of either *cis-9,trans-11-CLA* or LA in stimuli-containing medium. Basal cytokine expression in both cell lines was low. However, in the presence of 5 μg LPS and 10 serum secretion of both cytokines IL-6 and IL-8 significantly increased. In BEAS-2B, the basal cytokine expression was approximately 2.6-fold higher for IL-8 and 5.9-fold higher for IL-6 in the presence of the indicated stimuli (Fig 2A). When *cis-9,trans-11-CLA* was added to the cells sensitised IL-8 and IL-6 production was dose-dependently inhibited in a range from 25.6 ± 3.6 % in lowest, to 55.2 ± 5.2 % in highest

concentration and from 59.9 ± 7.1 % to 76.4 ± 4.4 %, respectively, compared with the stimulated control+. Decreased cytokine release was also noticed in the corresponding LA-cultures, but was less clear (by 19.3 ± 8.7 % to 33.5 ± 5.0 % reduced IL-8 and 23.1 ± 8.9 % to 50.2 ± 14.1 % reduced IL-6). NHBE cytokine release was massively sensitised by LPS- and serum stimulation. *Cis-9,trans-11*-CLA was similarly effective in suppressing cytokine secretion as seen for BEAS-2B. Significantly less IL-8 was quantified in *cis-9,trans-11*-CLA treated cells, whereas 10 μ g CLA/mL was most efficacious (by 46.0 ± 8.1 % compared to control+). CLA-mediated suppression of IL-6 production was even clearer. CLA added together with stimulating LPS and serum revealed a significant decrease in cytokine release in a dose-dependent manner (ranging from 56.9 ± 4.9 % to 68.6 ± 5.3 %). LA in highest concentration led to significant reduction in cytokine secretion just as well: IL-8 release was reduced by 43.3 ± 14.3 % and IL-6 release by 60.0 ± 16.3 . However, comparison of both fatty acids showed significant differences in modulating cytokine expression, The results are shown in Figures 2A and 2B.

In Table 1, all results are summarized. The percentage of inhibition of stimuli-induced cytokine release is comparatively higher than that seen for proliferation. By representing production of interleukins/100.000 cells, fatty acid-specific differences become distinct: all tested concentrations of *cis-9,trans-11*-CLA were more efficacious in inhibiting secretion of IL-6 compared with the corresponding LA-treatments. With regard to IL-8 release, the dose-dependent effects are less clear: in BEAS-2B only the highest concentration of the isomer, and in NHBE the middle and the lowest concentration, had a higher depressing effect on IL-8 production than LA.

Table 1

Comparison of percentages of inhibition relating to stimulated proliferation and IL-6 and IL-8 production after 24-h-treatment with *cis-9,trans-11*-CLA or LA and the means of cytokine release/100.000 cells

	% inhibition of			pg IL	pg IL
	proliferation	IL-6-secretion	IL-8-secretion		
BEAS-2B					
CLA 20 μg/mL	32.7 ± 5.0	76.4 ± 4.4	55.2 ± 5.2	792 ± 152	1458 ± 136
CLA 10 μg/mL	19.3 ± 5.0	69.7 ± 7.6	38.8 ± 5.2	841 ± 184	1667 ± 160
CLA 5 μg/mL	7.9 ± 5.1	59.9 ± 7.1	25.6 ± 3.6	983 ± 175	1774 ± 154
LA 20 μg/mL	4.7 ± 6.9	50.2 ± 14.1	33.5 ± 4.0	1181 ± 256	1533 ± 121
LA 10 μg/mL	no effect	38.4 ± 6.6	30.6 ± 3.6	1220 ± 120	1341 ± 110
LA 5 μg/mL	no effect	23.1 ± 8.9	19.3 ± 8.7	1440 ± 78	1483 ± 209

Table 1 (cont.)

Comparison of percentages of inhibition relating to stimulated proliferation and IL-6 and IL-8 production after 24-h-treatment with cis-9,trans-11-CLA or LA and the means of cytokine release/100.000 cells

	% inhibition of			pg IL	pg IL
	proliferation	IL-6-secretion	IL-8-secretion		
NHBE					
CLA 20 µg/mL	17.4 ± 2.8	68.6 ± 5.3	35.9 ± 11.4	1731 ± 387	6793 ± 545
CLA 10 µg/mL	15.4 ± 3.6	62.3 ± 10.2	46.0 ± 8.1	2062 ± 707	5659 ± 812
CLA 5 µg/mL	5.3 ± 3.7	56.9 ± 4.9	33.3 ± 8.1	2049 ± 262	6212 ± 513
LA 20 µg/mL	8.4 ± 2.1	60.0 ± 16.3	43.3 ± 14.3	2007 ± 924	5420 ± 1032
LA 10 µg/mL	no effect	35.0 ± 8.6	27.8 ± 10.8	2906 ± 530	6252 ± 462
LA 5 µg/mL	no effect	32.1 ± 5.6	22.8 ± 5.2	3052 ± 292	6820 ± 543

Example 2**Quantification of IL-6 and IL-8 mRNA**

Reverse transcriptase-polymerase chain reaction (RT-PCR) using cyclophilin RNA as internal standard was performed after 4 h and 12 h of incubation of cells without (c+) or with either 20 µg/mL cis-9,trans-11-CLA or LA in stimuli-containing medium. PCR reaction products were separated by flat bed electrophoresis, stained with ethidium bromide, recorded using a gel-documentation-system and analysed densitometrically. The effect of CLA on IL-6 and IL-8 protein levels paralleled mRNA levels. Compared with stimulated control (c+) the mRNA accumulation of both cytokines after the period of stimulation was found to be diminished by the isomer, whereas LA had no effect. Outcomes are presented in Figure 3.

Claims

1. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid (CLA) for making a medica-
5 ment for fighting inflammatory diseases.
2. Use according to claim 1, **characterised in** that said medicament acts against the hyper-
sensitivity of the bronchia.
- 10 3. Use according to claim 1, **characterised in** that said medicament acts against respiratory
diseases, particularly against asthma.
4. Use according to claim 1, **characterised in** that said medicament acts against rheumatic
diseases, particularly rheumatic arthritis.
- 15 5. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the inhibition of the prolifer-
ation of human or animal cells, particularly cells of the immune systems involved in
immune response.
- 20 6. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the support of apoptosis of
eosinophilic granulocytes.
7. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acid for the inhibition of specific
cytokine expression.
- 25 8. Use according to at least one of claims 1 to 7, **characterised in** that a technical grade CLA
is used, comprising said *cis*-9,*trans*-11 isomer in amounts of at least 30 % b.w. – calcu-
lated on the total CLA content.
- 30 9. Use according to at least one of claims 1 to 8, **characterised in** that a technical grade CLA
is used whose acyl moiety comprises at most 30 % b.w. *trans*-10,*cis*-12 isomers and in to-
tal less than 1 % b.w. 8,10-, 11,13 and *trans,trans* isomers – calculated on the total CLA
content.
- 35 10. Use according to at least one of claims 1 to 9, **characterised in** that said CLA or, as an
alternative, said medicament is applied sub-cutaneously, intramuscularly, per inhalation,
per infusionem, topically or orally.

11. Use of the *cis*-9,*trans*-11 isomer of conjugated linoleic acids as a nutrition, functional food or dietary supplement agent.
12. Use according to at least one of claims 1 to 11, **characterised in** that said CLA is applied
5 in amounts of from 0.05 to 5 g/day.

Figures

Figures 1A and 1B




Fig. 1A: Modulation of LPS/serum-stimulated BEAS-2B by *cis*-9,*trans*-11 CLA and LA. The cells were incubated with the fatty acids at increasing concentrations for 24 h. (A) shows relative cell numbers compared with the unstimulated control (= 1) (B) depicts relative stimulation or inhibition observed. Data are means \pm SEM of 6 independent experiments performed at different days ($n = 6$). Connection of bars represents data with statistically significant differences ($p < 0.05$)




Fig. 1B: Modulation of LPS/serum-stimulated NHBE by *cis*-9,*trans*-11 CLA and LA. The cells were incubated with the fatty acids at increasing concentrations for 24 h. (A) shows relative cell numbers compared with the unstimulated control (= 1) (B) depicts relative stimulation or inhibition observed. Data are means \pm SEM of 6 independent experiments performed at different days ($n = 6$). Connection of bars represents data with statistically significant differences ($p < 0.05$)

Figures 2A and 2B




Fig. 2A: Effects of *cis*-9,*trans*-11-CLA and LA on the production of IL-8 (a) and IL-6 (b) by stimulated BEAS-2B after 24 h. Cells were incubated in the presence of 5 µg LPS and 10 % serum and different concentrations of either *cis*-9,*trans*-11-CLA or LA for 24 h and the supernatants were assessed for the concentration of cytokines. Data are shown as means ± SEM (n = 6), connection of bars represents data with statistically significant differences (p<0.05).





Fig. 2B: Effects of *cis*-9,*trans*-11-CLA and LA on the production of IL-8 (a) and IL-6 (b) by stimulated BEAS-2B after 24 h. Cells were incubated in the presence of 5 µg LPS and 10 % serum and different concentrations of either *cis*-9,*trans*-11-CLA or LA for 24 h and the supernatants were assessed for the concentration of cytokines. Data are shown as means ± SEM (n = 6), connection of bars represents data with statistically significant differences (p<0.05).

Figure 3

5 **Fig. 3:** The expression of IL-8 (a) and IL-6 mRNA (b) in LPS- and serum-stimulated BEAS-2B over a 4-h and 12-h period of treatment without(c+) or with 20 μ g cis-9,trans-11-CLA or LA/mL. Total RNA was extracted and processed for RT-PCR. Cyclophilin was used as housekeeping gene. Data are shown as means \pm SEM ($n = 4$).

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/14592

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/201 A61P11/00 A61P11/06 A61P19/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 319 950 B1 (SEIDEL MICHAEL C) 20 November 2001 (2001-11-20) column 15, line 5 - line 29 column 5, line 57 - line 59 claims 1-20 ---	1-12
X	WO 01/05395 A (WISCONSIN ALUMNI RES FOUND) 25 January 2001 (2001-01-25) claims 1-7 ---	1-12
X	EP 0 955 047 A (UNIV GEORGE WASHINGTON) 10 November 1999 (1999-11-10) claims 1-10 page 3, paragraph 14 page 4, paragraph 20 - paragraph 21 --- -/--	1-12

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

19 April 2004

Date of mailing of the international search report

27/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/EP 03/14592

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 097 708 A (UNILEVER PLC ;UNILEVER NV (NL)) 9 May 2001 (2001-05-09) claims 1-14	1-12
A	WHIGHAM L D ET AL: "CONJUGATED LINOLEIC ACID REDUCED ANTIGEN-INDUCED PROSTAGLANDIN E2 RELEASE FROM SENSITIZED TRACHEAS" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 12, no. 5, 1998, page A819 XP000914686 ISSN: 0892-6638 the whole document	1-12
A	YU Y ET AL: "Conjugated linoleic acid decreases production of pro-inflammatory products in macrophages: evidence for a PPARgamma-dependent mechanism" BIOCHIMICA AND BIOPHYSICA ACTA. MOLECULAR AND CELL BIOLOGY OF LIPIDS, ELSEVIER, AMSTERDAM, NL, vol. 1581, no. 3, 15 April 2002 (2002-04-15), pages 89-99, XP004357463 ISSN: 1388-1981 the whole document	1-12
A	MCCARTY M F: "DOWNREGULATION OF MACROPHAGE ACTIVATION BY PPAR GAMMA SUGGESTS A ROLE FOR CONJUGATED LINOLEIC ACID IN PREVENTION OF ALZHEIMER'S DISEASE AND ATHEROSCLEROSIS" JOURNAL OF MEDICINAL FOOD, MARY ANN LIEBERT, LARCHMONT, NY,, US, vol. 1, no. 3, 1998, pages 217-226, XP000920842 ISSN: 1096-620X the whole document	1-12
A	TUREK J J ET AL: "MODULATION OF MACROPHAGE CYTOKINE PRODUCTION BY CONJUGATED LINOLEICACIDS IS INFLUENCED BY THE DIETARY N-6:N-3 FATTY ACID RATIO" JOURNAL OF NUTRITIONAL BIOCHEMISTRY, BUTTERWORTH PUBLISHERS, STONEHAM, GB, vol. 9, no. 5, 1998, pages 258-266, XP000920933 ISSN: 0955-2863 the whole document	1-12

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/14592

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6319950	B1	20-11-2001	US 5892074 A	06-04-1999
			US 2001018453 A1	30-08-2001
			US 6153774 A	28-11-2000
			US 6160141 A	12-12-2000
WO 0105395	A	25-01-2001	US 6077868 A	20-06-2000
			AU 3772000 A	05-02-2001
			CA 2379649 A1	25-01-2001
			EP 1196161 A1	17-04-2002
			WO 0105395 A1	25-01-2001
EP 0955047	A	10-11-1999	US 6077525 A	20-06-2000
			CA 2268567 A1	10-10-1999
			EP 0955047 A2	10-11-1999
EP 1097708	A	09-05-2001	EP 1097708 A1	09-05-2001
			AT 249822 T	15-10-2003
			DE 60005272 D1	23-10-2003
			DE 60005272 T2	08-04-2004